Home › Funds › SUPERSTRING CAPITAL MANAGEMENT LP › URGN

SUPERSTRING CAPITAL MANAGEMENT LP position in URGN

UROGEN PHARMA LTD · Health Care

SUPERSTRING CAPITAL MANAGEMENT LP reported holding 191,313 shares of URGN (UROGEN PHARMA LTD) in its Q2 2026 13F filing — a position valued at US$7.0M, representing 4.45% of its reported portfolio and ranking #10 among its reported holdings. SUPERSTRING CAPITAL MANAGEMENT LP has disclosed URGN holdings in 9 of the last 11 reported quarters, going back to Q4 2023.

Latest position (Q2 2026)191.31K sh
Reported value held$7.04M
Portfolio Weight4.45%
First reportedQ4 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How SUPERSTRING CAPITAL MANAGEMENT LP's URGN position evolved

SUPERSTRING CAPITAL MANAGEMENT LP first disclosed a stake in URGN in Q4 2023 at 255,430 shares (US$3.8M). The position peaked in Q4 2025 at 718,354 shares, worth US$16.8M. Across 9 filings, SUPERSTRING CAPITAL MANAGEMENT LP increased the stake 3 time(s), trimmed it 3 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 191,313 shares valued at US$7.0M — a reduction of -196,058 shares quarter over quarter.. Notable position changes include a 79% trim in Q2 2025 (shares rose 46% over the following quarter), a 717% increase in Q4 2025 (shares fell 23% over the following quarter), a 51% trim in Q2 2026 (shares rose 10% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 255.43K $3.83M New
Q1 2024 288.27K $4.32M Add
Q4 2024 301.21K $3.21M New
Q1 2025 423.63K $4.69M Add
Q2 2025 87.91K $1.20M Reduce
Q3 2025 87.91K $1.75M Hold
Q4 2025 718.35K $16.82M Add
Q1 2026 387.37K $6.96M Reduce
Q2 2026 191.31K $7.04M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About URGN and 13F data

URGN (UROGEN PHARMA LTD) is a Health Care company. 39 other funds we track also report a position in URGN — the largest reported positions include RTW INVESTMENTS, LP (US$167.2M), Kynam Capital Management, LP (US$89.6M), Jefferies Financial Group Inc. (US$80.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding URGN

All URGN fund holders →

FAQ

How long has SUPERSTRING CAPITAL MANAGEMENT LP held URGN?

SUPERSTRING CAPITAL MANAGEMENT LP has disclosed URGN holdings in 9 of the last 11 reported quarters, going back to Q4 2023.

What is SUPERSTRING CAPITAL MANAGEMENT LP's current position in URGN?

As of Q2 2026, SUPERSTRING CAPITAL MANAGEMENT LP holds 191.31K shares of URGN (UROGEN PHARMA LTD), valued at $7.04M, representing 4.45% of its reported portfolio and ranking #10.

Has SUPERSTRING CAPITAL MANAGEMENT LP been buying or selling URGN?

In the latest 13F filing (Q2 2026), SUPERSTRING CAPITAL MANAGEMENT LP reduced its position in URGN. The position peaked in Q4 2025 at 718.35K shares.

Which other funds hold URGN?

Other major institutional holders of URGN include RTW INVESTMENTS, LP, Kynam Capital Management, LP, Jefferies Financial Group Inc., among 39 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.